nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—TNFSF11—jaw skeleton—cleft lip	0.131	0.234	CbGeAlD
Lenalidomide—TNFSF11—periosteum—cleft lip	0.0987	0.176	CbGeAlD
Lenalidomide—TNFSF11—skull—cleft lip	0.0811	0.145	CbGeAlD
Lenalidomide—TNFSF11—cartilage tissue—cleft lip	0.0692	0.124	CbGeAlD
Lenalidomide—CDH5—Adherens junctions interactions—PVRL1—cleft lip	0.0634	0.153	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—NOG—cleft lip	0.0469	0.113	CbGpPWpGaD
Lenalidomide—TNFSF11—tongue—cleft lip	0.0418	0.0746	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—TGFB3—cleft lip	0.041	0.0988	CbGpPWpGaD
Lenalidomide—CDH5—Cell-cell junction organization—PVRL1—cleft lip	0.0364	0.0879	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—NODAL—cleft lip	0.033	0.0796	CbGpPWpGaD
Lenalidomide—TNFSF11—mouth—cleft lip	0.0281	0.0501	CbGeAlD
Lenalidomide—CDH5—Cell junction organization—PVRL1—cleft lip	0.0276	0.0665	CbGpPWpGaD
Lenalidomide—Thalidomide—FGFR2—cleft lip	0.0254	1	CrCbGaD
Lenalidomide—TNFSF11—Differentiation Pathway—FGF8—cleft lip	0.0237	0.0572	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—BMP4—cleft lip	0.0229	0.0552	CbGpPWpGaD
Lenalidomide—TNFSF11—embryo—cleft lip	0.02	0.0357	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—PVRL1—cleft lip	0.0196	0.0474	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—FGF10—cleft lip	0.0159	0.0383	CbGpPWpGaD
Lenalidomide—CDH5—embryo—cleft lip	0.0151	0.0269	CbGeAlD
Lenalidomide—PTGS2—periosteum—cleft lip	0.0128	0.0229	CbGeAlD
Lenalidomide—TNFSF11—head—cleft lip	0.0101	0.0181	CbGeAlD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—NOS3—cleft lip	0.00997	0.024	CbGpPWpGaD
Lenalidomide—CRBN—embryo—cleft lip	0.00957	0.0171	CbGeAlD
Lenalidomide—PTGS2—cartilage tissue—cleft lip	0.009	0.0161	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—FGF2—cleft lip	0.00866	0.0209	CbGpPWpGaD
Lenalidomide—CRBN—telencephalon—cleft lip	0.00778	0.0139	CbGeAlD
Lenalidomide—CDH5—head—cleft lip	0.00763	0.0136	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—MYC—cleft lip	0.00576	0.0139	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—BHMT2—cleft lip	0.00573	0.0138	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—cleft lip	0.0049	0.0118	CbGpPWpGaD
Lenalidomide—CRBN—head—cleft lip	0.00485	0.00865	CbGeAlD
Lenalidomide—ABCB1—ABC-family proteins mediated transport—ABCA4—cleft lip	0.00397	0.00959	CbGpPWpGaD
Lenalidomide—PTGS2—mouth—cleft lip	0.00365	0.00653	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—ARHGAP29—cleft lip	0.00348	0.0084	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NOS3—cleft lip	0.00341	0.00823	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NOS3—cleft lip	0.00322	0.00777	CbGpPWpGaD
Lenalidomide—PTGS2—embryo—cleft lip	0.00261	0.00465	CbGeAlD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—cleft lip	0.00253	0.00611	CbGpPWpGaD
Lenalidomide—PTGS2—telencephalon—cleft lip	0.00212	0.00378	CbGeAlD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—TCN2—cleft lip	0.0021	0.00506	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—WNT9B—cleft lip	0.00191	0.0046	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOG—cleft lip	0.00183	0.00441	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ABCA4—cleft lip	0.0017	0.0041	CbGpPWpGaD
Lenalidomide—ABCB1—embryo—cleft lip	0.00161	0.00288	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—WNT3—cleft lip	0.00152	0.00366	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTR—cleft lip	0.00145	0.00351	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MTR—cleft lip	0.00144	0.00347	CbGpPWpGaD
Lenalidomide—PTGS2—head—cleft lip	0.00132	0.00236	CbGeAlD
Lenalidomide—ABCB1—telencephalon—cleft lip	0.00131	0.00234	CbGeAlD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NODAL—cleft lip	0.00112	0.0027	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SPRY2—cleft lip	0.001	0.00242	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGF7—cleft lip	0.001	0.00242	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGF8—cleft lip	0.000925	0.00223	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTCH1—cleft lip	0.00083	0.002	CbGpPWpGaD
Lenalidomide—ABCB1—head—cleft lip	0.000816	0.00146	CbGeAlD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NODAL—cleft lip	0.000793	0.00191	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cleft lip	0.000778	0.00188	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—cleft lip	0.000771	0.00186	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGF3—cleft lip	0.000753	0.00182	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGF9—cleft lip	0.000734	0.00177	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGF10—cleft lip	0.000619	0.00149	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—cleft lip	0.000599	0.00145	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGFR2—cleft lip	0.000497	0.0012	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—cleft lip	0.000475	0.00115	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGFR1—cleft lip	0.000463	0.00112	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGFR3—cleft lip	0.000438	0.00106	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCA4—cleft lip	0.000415	0.001	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—cleft lip	0.000404	0.000974	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGFR1—cleft lip	0.000402	0.000969	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—cleft lip	0.00037	0.000893	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—WNT9B—cleft lip	0.000368	0.000887	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGF2—cleft lip	0.000338	0.000816	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—cleft lip	0.000337	0.000812	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOS3—cleft lip	0.000334	0.000805	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ABCA4—cleft lip	0.000328	0.00079	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC19A1—cleft lip	0.0003	0.000723	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.000293	0.000708	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—WNT3—cleft lip	0.000292	0.000704	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGFR1—cleft lip	0.000285	0.000687	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—cleft lip	0.000282	0.00068	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC19A1—cleft lip	0.000251	0.000605	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TCN2—cleft lip	0.000248	0.000599	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MYC—cleft lip	0.000221	0.000533	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.000208	0.000502	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TCN2—cleft lip	0.000208	0.000502	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SPRY2—cleft lip	0.000193	0.000466	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF7—cleft lip	0.000193	0.000466	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.000192	0.000463	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF8—cleft lip	0.000178	0.00043	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC19A1—cleft lip	0.000178	0.000429	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTR—cleft lip	0.000172	0.000415	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TCN2—cleft lip	0.000147	0.000356	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF3—cleft lip	0.000145	0.00035	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTR—cleft lip	0.000144	0.000348	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF9—cleft lip	0.000141	0.000341	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.000136	0.000328	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF10—cleft lip	0.000119	0.000288	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTR—cleft lip	0.000102	0.000246	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR2—cleft lip	9.57e-05	0.000231	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTHFR—cleft lip	9.21e-05	0.000222	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR1—cleft lip	8.92e-05	0.000215	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TYMS—cleft lip	8.83e-05	0.000213	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR3—cleft lip	8.43e-05	0.000203	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTHFR—cleft lip	7.72e-05	0.000186	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF2—cleft lip	6.52e-05	0.000157	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS3—cleft lip	6.43e-05	0.000155	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TYMS—cleft lip	6.26e-05	0.000151	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTHFR—cleft lip	5.47e-05	0.000132	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NOS3—cleft lip	5.38e-05	0.00013	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—cleft lip	4.26e-05	0.000103	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NOS3—cleft lip	3.81e-05	9.2e-05	CbGpPWpGaD
